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Abstract
Purpose The local renin–angiotensin system has been held to
be expressed in many organs, including the eye. It has an
important role in the regulation of local fluid homeostasis, cell
proliferation, fibrosis, and vascular tone. Mas-receptor (Mas-
R) is a potential receptor acting mainly opposite to the well-
known angiotensin II receptor type 1. The aim of this study
was to determine if Mas-R is expressed in the human eye.
Methods Seven enucleated human eyes were used in immu-
nohistochemical detection of Mas-R and its endogenous li-
gand angiotensin (1–7) [Ang(1–7)]. Both light microscopy
and immunofluorescent detection methods were used. A hu-
man kidney preparation sample was used as control.
Results The Mas-R was found to have nuclear localization,
and localized in the retinal nuclear layers and in the structures
of the anterior segment of the eye. A cytoplasmic immuno-
staining pattern of Ang(1–7) was found in the inner and outer
nuclear and plexiform layers of the retina and in the ciliary
body.
Conclusion To the best of our knowledge, this is the first
report showing Mas-R expression in the human eye. Its
localization suggests that it may have a role in physiological
and pathological processes in the anterior part of the eye and
in the retina.
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Introduction
The systemic renin–angiotensin system (RAS) regulates
body fluid balance, blood pressure, and many cardiovas-
cular responses via endocrine mechanisms. Vasoconstric-
tive angiotensin II (Ang II) has a key role in RAS by
acting mainly via the angiotensin type 1 receptor
(AT1-R) [1, 2]. In addition to the classical AT1-R and
angiotensin type 2 (AT2-R) receptors, another angioten-
sin receptor type, a Mas-receptor (Mas-R), has been
identified [3, 4]. Many of the Mas-R effects are opposite
to those of AT1-R. Both have important but opposite
roles in the regulation of local fluid homeostasis, cell
proliferation, fibrosis, and vasodilatation. Mas-R is acti-
vated by an endogenous heptapeptide, angiotensin 1–7
[Ang (1–7)], which in turn is a degradation product of
octapeptide Ang II (see Fig. 1 illustrating the RAS cas-
cade). In addition to the systemic RAS, a local tissue
RAS has been identified in which long-term changes
are regulated by autocrine and paracrine mechanisms
[5]. Local RAS has been widely described in the heart,
kidney, and adrenal tissue, but also in other organs such
as the brain, reproductive system, intestine [5–7], and the
eye [8–14]. The present study was designed to investi-
gate localization of Mas-R and Ang(1–7) in the human
eye using immunohistochemistry.
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Materials and methods
Eyes and fine-needle samples of the kidney
The study was approved by the local ethical committee (Re-
gional Ethics Committee of the Expert Responsibility Area of
Tampere University Hospital, R10155). Seven human eyes
were used for detection of Mas-R and its endogenous ligand
Ang(1–7). The eyes had earlier been enucleated due to ocular
malignancies (all melanomas) at the Tampere University Hos-
pital Eye Center, Tampere, Finland, and were stored in paraf-
fin blocks after removal. As control tissue we used human
kidney fine-needle samples originally taken at the Tampere
University Hospital for other purposes. The kidney samples
were stored in paraffin as well.
Immunohistochemistry
We used antibodies against Ang(1–7) Mas receptor (AAR
013, Alomone Labs Ltd, Jerusalem, Israel) and Ang-I(1–7)/
AngII(1–7) (H-002-24, Phoenix Pharmaceuticals, Inc., Bur-
lingame, CA, USA). The antigen reactivity of both agents
has been confirmed for humans but also for the rat (data not
shown). For immunohistochemistry we used 4 μm-thick par-
affin sections that were cut onto SuperFrost plus microscopic
s l ides (Menze l -Gläser, Gerhard Menze l GmbH,
Fig. 1 A RAS cascade.
ACE=angiotensin-converting
enzyme,
ACE2=angiotensin-converting
enzyme-related
carboxypeptidase, Ang
I,II,III,IV=angiotensin I,II,III,IV,
Ang (1–10)=angiotensin (1–10),
Ang (1–8)=angiotensin (1–8),
Ang (2–8)=angiotensin (2–8),
Ang (3–8)=angiotensin (3–8),
Ang (1–9)=angiotensin (1–9),
Ang (1–7)=angiotensin (1–7),
Ang (1–5)=angiotensin (1–5),
Ang (3–7)=angiotensin (3–7),
AT1=angiotensin II type 1
receptor, AT2=angiotensin II type
2 receptor, AT4=angiotensin II
type 4 receptor,
AP=aminopeptidase
(−A,-N,-M,-B),
CAGE=chymostatin-sensitive
Ang II-generating enzyme,
Mas-receptor=Ang (1–7)
receptor type, Nep=neprilysin,
PEP=prolyl endopeptidase,
PC-P = prolylcarboxy-peptidase,
tPA=tissue-type plasminogen
activator. (Vaajanen et al. 2008a, a
modified version)
Fig. 2 Expression of
Mas-receptor in the human
kidney. aMas-R (in red, black
arrows) is especially found in the
cells of glomerulus, tubulus and
vascular endothelium. b No
corresponding staining was
observed in the negative control
sample by omission of primary
antibodies. Magnification 200×
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Braunschweig, Germany). The sections were dried at +60 °C
for 1 h. Antigen retrieval was performed on re-hydrated sec-
tions in a microwave oven at 850 W twice for 7 min using
10 mM Tris 1 mM EDTA retrieval buffer (pH 9.0) as retrieval
solution.
Light microscopy
Endogenous peroxidase activity was blocked with
phosphate-buffered saline (PBS) and H2O2 solution
(0.3 %) for 30 min in determination of Mas-R and real
peroxidase blocking solution (S2023, DAKO, Glostrup,
Denmark) for 5 min in determination of Ang(1–7); there-
after, the samples were rinsed with PBS containing
Tween 20. Normal goat serum (50062Z, Invitrogen, Life
Technologies, Carlsbad, CA, USA) was used to prevent
non-specific staining for 30 min, and then blotted off.
AAR 013 was diluted (1:300) in PBS (pH 7.2) contain-
ing 0.1 % bovine serum albumin (BSA, A-4503, Sigma,
Saint Louis, MO, USA) and incubated for 30 min at +
37 °C. H-002-24 was diluted (1:200) in DAKO antibody
diluent (S2022, DAKO) at pH 7.2 and incubated for
1 hour at room temperature (RT). Immunostaining was
carried out using goat anti-rabbit Ig HRP (1:200, P0448,
DAKO) for 30 min as secondary antibody for AAR 013,
and Nischirei Histofine (Nischirei Biosciences Inc., To-
kyo, Japan) for 30 min for H-002-24. Separate Nischirei
Histofine was used for human (414141 F) and rat
(434181 F) samples. Aminoethylcarbazole (Vector Labo-
ratories, Burlingame, CA, USA) was used as chromogen
and hematoxylin (Merck KGaA, Darmstadt, Germany) as
counterstain.
Fluorescent microscopy
After antigen retrieval, the sections were washed with PBS
containing Tween 20 and primary antibodies AAR 013
(1:300) and H-002-24 (1:200) were diluted in DAKO anti-
body diluent (S2022, DAKO) and incubated overnight at
RT. Then the sections were rinsed with PBS-Tween 20 and
goat anti-rabbit Alexa Fluor 488 (1:500, Invitrogen, Life
Technologies) were applied for 3 hours at RT. In order to
conf i rm the nuc lea r loca l iza t ion of Mas-R, we
double-stained sections with mouse anti-human NCL-Emerin
Fig. 3 Expression of Mas-R in the human retina. a The intensive Mas-R
staining (in red) was seen in the inner nuclear layer, where most of the
cells expressedMas-R protein. In addition, there were positive cells in the
outer nuclear layer of the retina and in the ganglion cell layer cells and
retinal pigment epithelium cells. Black arrows indicate some staining
marks of the Mas-R. b No Mas-R immunoreactivity was detected in the
negative control sample, which was counterstained (in blue) to reveal
retinal layers. Magnification 200×. RPE=retinal pigment epithelium,
ONL=outer nuclear layer, INR=inner nuclear layer, RGCL=retinal gan-
glion cell layer
Fig. 4 Expression of Mas-R in the human ciliary body. a In ciliary body,
Mas-R expression (in red) was high in non-pigmented cells of the ciliary
epithelium. The pigment epithelium cells were also strongly stained. In
addition, some cells in the trabecular meshwork and in the wall of
Schlemm’s canal were stained (not illustrated in figures). b No Mas-R
immunoreactivity was detected in the negative control sample, which was
counterstained (in blue) to reveal retinal layers. Magnification 200×
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(1:20, clone 4G5, Leica Biosystems Newcastle Ltd., Newcas-
tle Upon Tyne, UK), which specifically labels the nuclear
envelope. The cellular-specific presence of Mas-R and
Ang(1–7) was investigated by employing antibodies directed
against neuronal nuclei (NeuN, 1:100, MAB377, EMD
Millipore, Billerica, MA, USA), glial fibrillary acidic protein
(GFAP, 1:200, clone 1B4, BD Pharmingen, BD Biosciences,
San Jose, CA, USA) that labels retinal astrocytes and activated
Müller cells, and endothelial cell marker CD31 (1:100,
ab28364, Abcam, Cambridge, MA, USA). Second primary
antibodies were diluted in DAKO antibody diluent (S2022,
DAKO) and incubated overnight at RT. Then the sections
were rinsed with PBS-Tween 20, and goat anti-mouse Alexa
Fluor 594 IgG (1:500, Invitrogen, Life Technologies) were
applied for 3 hours at RT. The sections were coverslipped
using Vectashield mounting medium with DAPI (H-1200,
Vector Laboratories, Inc., Burlingame, CA, USA). The sec-
tions were analyzed using Zeiss LSM 700 confocal micro-
scope (Carl Zeiss, Germany).
Negative controls
The sections were stained both by omitting primary and by
omitting secondary antibody. In addition, the pre-adsorption
Fig. 5 Immunohistochemical
staining of Mas-R in the human
cornea. aMany of the basal and
superobasal epithelial cells were
stained (in red, indicated by black
arrows). b No corresponding
staining was observed in the
negative control sample.
Magnification 200×
Fig. 6 Photomicrographs demonstrating counterstain DAPI (in blue),
Emerin, CD31 and GFAP (all in red) and Mas-R (in green). Nuclear
localization of Mas-R was found in the ciliary body (a–d), choroid (e–
h) and retina (i–k). Pre-adsorption control did not show the corresponding
Mas-R immunoreactivity (l).White arrows in c and d indicate some cells
that colocolized Emerin and Mas-R (in yellow in d), whereas white
arrows in f–h point to CD31-immunoreactive cells of choroid that are
immunonegative for Mas-R. However, white arrowheads in f–h indicate
endothelial cell that has nuclearMas-R immunoreactivity. RGCL = retinal
ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer
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control where antibody against Mas-R was pre-adsorbed with
antigenic peptide was used. No corresponding staining was
observed in any of the negative control samples.
Results
Expression of Mas-receptors
Mas-R is well known to be expressed in the kidney, adrenals,
and vascular system cells [4–6] . Therefore, we chose human
kidney tissue as positive control for the antibody recognizing
Mas-R. In the kidney tissue, Mas-R was mainly expressed in
the tubular and glomerular cells and vascular endothelium
(Fig. 2).
Next, we immunostained human eye sections using the
same antibody. Mas-R was widely expressed in the eye struc-
tures. In the retina, Mas-R was found in the nuclear layers as
well as in the retinal pigment epithelium and choroid (Fig. 3).
In ciliary body, Mas-R was expressed by non-pigmented cells
and the ciliary epithelium (Fig. 4). Mas-R immunoreactivity
was also observed in the trabecular meshwork and in the wall
of Schlemm’s canal. In the human cornea, the majority of the
basal and superobasal epithelial cells were immunopositive
for Mas-R (Fig. 5).
To verify subcellular localization of Mas-R, we used dou-
ble immunofluorescent staining of sections with antibody di-
rected against Emerin, a nuclear envelope protein. In corneal,
ciliary body, retinal, and choroid cells, Mas-R immunoreac-
tivity was exclusively localized in the nucleus of cells (Fig. 6).
Expression of Ang(1–7)
Ang(1–7) expression was first verified in the human kid-
ney tissue. Thereafter, Ang(1–7) expression was identi-
fied in the human ocular sections. Similarly to Mas-R
immunoreactivity, Ang(1–7) was widely expressed in
the ocular tissue. We found Ang(1–7) immunoreactivity
in the inner and outer nuclear and plexiform layers of
retina, choroid, non-pigmented, and pigmented epithelial
cells of the ciliary body (Fig. 7). In contrast to Mas-R
immunoreactivity, Ang(1–7) was expressed in the cyto-
plasm of cells and in some cells colocalized with neuro-
nal marker NeuN, glial cell marker GFAP and endothe-
lial cell marker CD31 (Fig. 8).
Fig. 7 Expression of cytoplasmic
Ang(1–7) in the human retina and
ciliary body. Aweak
immunostaining of Ang(1–7) was
found in the inner and outer
nuclear and plexiform layers of
retina a In the ciliary body there
was a cytoplasmic stain in the
non-pigmented and pigmented
epithelial cells (c). Magnification
200×. A human kidney sample is
shown in e. Magnification 400×.
In all figures, red–brown color
indicates staining of Ang (1–7),
see black arrows. b, d, f Show
negative staining samples without
labelling antibody. RGCL=retinal
ganglion cell layer, IPL =inner
plexiform layer, INL=inner
nuclear layer, OPL=outer
plexiform layer, ONL =outer
nuclear layer, OS=outer segment,
RPE=retinal pigment epithelium,
Ch=choroidea
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Discussion
In this study, we describe Mas-R and its endogenous ligand
Ang(1–7) immunoreactivity and cellular localization in hu-
man ocular tissue. We found that Mas-R is widely expressed
in the eye, with primarily nuclear localization in cells. Ang(1–
7) was also found in different structures of the eye, but with
cytoplasmic localization in cells. Previously, our research
group has described Mas-R expression in the rat eye using
the RT-PCR method [15].
Mas-Rwas first discovered byYoung et al. (1986) as proto-
oncogene almost three decades ago [3]. Later, the same group
reported high Mas-R levels in the rat central nervous system
[16]. Two decades ago, Kitaoka and co-workers (1994) dem-
onstrated Mas-R expression in the eyes of rhesus macaque
using in-situ hybridization and epi-polarization microscopy
[17]. The authors concluded that Mas-R could be used as a
specific marker for retinal pigment epithelium cells [17].
However, the functional significance of Mas-R and its puta-
tive ligand Ang(1–7) expression in the ocular structures re-
mains unknown. Mas-R is an important member of the local
tissue RAS, acting mainly opposite to the well-known AT1-R.
Mas-R participates in cell proliferation and antifibrosis as well
as vasodilatation and local fluid volume homeostasis. In fact,
the potentials of Mas-R ligands, e.g. Ang(1–7) and active
enzymes such as ACE2 in degrading vasoconstrictive Ang II
to vasodilatory peptides constitute a present focus of cardio-
vascular drug development [18–20]. Most components of the
local RAS have already been widely identified in eye struc-
tures [10, 21]. However, further studies are required to identify
the specific physiologic role of local RAS in the human eye
and possible involvement in such pathological conditions as
diabetic retinopathy, age-related macular degeneration, and
glaucoma.
In a previous in-vivo study, we found that intraocular
administration of Mas-R agonist Ang(1–7) lowers intra-
ocular pressure (IOP) in normotensive rabbit eyes with-
out influence on aqueous humor outflow facility [21]. In
human studies, orally administered ACE inhibitor
(Captopril) and AT1-R antagonist (Losartan) reduced
IOP in both ocular normotensive and glaucomatous sub-
jects [22, 23]. Oculohypotensive effects of ACE inhibitor
Perindopril have also been reported in both acute and
chronic experimental models of glaucoma [24], as
Fig. 8 Colocalization of Ang(1–
7) (in green) with Emerin (red in
a–d), CD31 (red in e–h), NeuN
(red in i–l) and GFAP (red in m–
p). Blue color in all
photomicrographs indicates
counterstain with DAPI. c and d
White arrows indicate
cytoplasmic localization of
Ang(1–7) in ciliary body. f–h
White arrows point to
CD31-immunoreactive cells
localized in the retina and
containing Ang(1–7). i–l White
arrows indicate
NeuN-immunoreactive neurons
from the retinal ganglion cell
layer, which also contain Ang(1–
7) expression. m–p Retinal glia
overexpress GFAP. Some areas
(white arrows in n–p) show
colocalization of GFAP and
Ang(1–7). RGCL = retinal gan-
glion cell layer, IPL = inner
plexiform layer, INL = inner
nuclear layer, OPL = outer
plexiform layer, ONL = outer
nuclear layer
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recently also the anti-glaucomatous effects of the activa-
tion of intrinsic angiotensin-converting enzyme 2 in an
experimental glaucoma [9]. Our data from human eyes
indicate that Mas-R is localized in the human non-
pigmented epithelial cells of the ciliary body as well as
in the cells of trabecular meshwork. The latter suggests
that the aqueous humor production and outflow may be
influenced by Mas-R and its ligand Ang(1–7). However,
further studies are needed to confirm that.
To conclude, expression of RAS components and their cel-
lular localization suggest their involvement in controlling
aqueous humour dynamics and intraocular pressure. Further-
more, our descriptive data suggest that RAS may influence
pathophysiology of ocular diseases affecting ocular blood
flow and vasculature such as diabetic retinopathy. However,
further studies are needed to understand the functional signif-
icance of the local RAS in the eye.
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